Abingdon Health PLC (ABDX:AIM) delivered a confident investor presentation outlining strong operational and financial progress for FY2025, highlighting results in line with broker forecasts and significant H2 momentum driven by new contract wins and post-period deal flow. CFO Tom Hayes reported revenue growth supported by acquisitions of IVDeology and CS Life Sciences, which expanded the company’s regulatory capabilities, and a recent £3.2 million fundraising aimed at accelerating US manufacturing and supporting larger CDMO contracts. Executive Chairman Chris Hand emphasized Abingdon’s evolution into a full-service diagnostics partner, combining lateral flow development, regulatory expertise, and performance evaluation through its expanded UK sites and new Madison, Wisconsin facility. The company’s U.S. subsidiary, led by co-founder Chris Yates, has rapidly gained traction with six active contracts and growing demand for domestic production. Product innovation remains central to Abingdon’s strategy, including the AppDX AI-powered smartphone reader, eco-friendly red seaweed-based test cassettes, and partnerships for infectious disease diagnostics such as malaria and avian flu. Management reiterated that momentum has continued into FY2026, with market forecasts from Zeus projecting breakeven at adjusted EBITDA level and cash flow positivity during calendar 2026. The leadership team underlined their focus on scaling growth while maintaining shareholder alignment through disciplined capital deployment and a robust international expansion plan.